Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1 1

Status

Recruiting 4Completed 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Non-Small-Cell Lung 115Squamous Cell Carcinoma of Head and Neck 61Triple Negative Breast Neoplasms 57Melanoma 54Neoplasm Metastasis 49Lung Neoplasms 49Breast Neoplasms 41Neoplasms 36Colorectal Neoplasms 35Head and Neck Neoplasms 25Endometrial Neoplasms 25Carcinoma, Renal Cell 24Uterine Cervical Neoplasms 21Stomach Neoplasms 21Ovarian Neoplasms 21Carcinoma, Transitional Cell 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 18Esophageal Neoplasms 16Recurrence 15Carcinoma, Hepatocellular 14Pancreatic Neoplasms 13Sarcoma 12Carcinoma, Squamous Cell 12Glioblastoma 11Esophageal Squamous Cell Carcinoma 11Carcinoma 11Prostatic Neoplasms 10Brain Neoplasms 10Carcinoma, Merkel Cell 9

Interventions

pembrolizumab 4enfortumab vedotin 4Specimen Handling 3Magnetic Resonance Spectroscopy 3tamibarotene 1Standard of Care 1Radiotherapy 1Practice Guidelines as Topic 1Plasmapheresis 1Plasma Exchange 1Nephroureterectomy 1Morphine 1Hyperthermia, Induced 1Cystectomy 1Cisplatin 1Central Venous Catheters 1Bupivacaine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Ureteral Neoplasms × pembrolizumab × Clear all
NCT05614739 2026-05-19

FORAGER-1

Eli Lilly and Company

Phase 1 Recruiting
535 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

NCT07087860 2026-05-08

RECIPE-B1

Mayo Clinic

Phase 2 Recruiting
70 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic

Phase 4 Recruiting
75 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Emory University

Phase 2 Recruiting
25 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡